Literature DB >> 17283286

Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy.

Gregor Hasler1, Jan Willem van der Veen, Toni Tumonis, Noah Meyers, Jun Shen, Wayne C Drevets.   

Abstract

CONTEXT: Increasing evidence indicates that major depressive disorder (MDD) is associated with altered function of the major excitatory and inhibitory neurotransmitters glutamate and gamma-aminobutyric acid (GABA), respectively. A recently developed magnetic resonance spectroscopy method allows for reliable measurement of glutamate/glutamine (Glx) and GABA concentrations in prefrontal brain regions that have been implicated in the pathophysiologic mechanisms of MDD by studies using other neuroimaging and postmortem techniques.
OBJECTIVE: To measure Glx and GABA levels in 2 regions of the prefrontal brain tissue in unmedicated adults with MDD.
DESIGN: Cross-sectional study for association.
SETTING: Psychiatric outpatient clinic. PARTICIPANTS: Twenty unmedicated, depressed patients with MDD and 20 age- and sex-matched controls. Intervention Participants underwent scanning using a 3-T whole-body scanner with a transmit-receive head coil, providing a homogeneous radiofrequency field and the capability of obtaining spectroscopic measurements in a dorsomedial/dorsal anterolateral prefrontal region of interest (ROI) and a ventromedial prefrontal ROI. MAIN OUTCOME MEASURES: Glx and GABA levels derived from magnetic resonance spectroscopy signals.
RESULTS: Depressed patients had reduced Glx levels in both ROIs. The GABA levels were reduced in the dorsomedial/dorsal anterolateral prefrontal ROI. Levels of GABA and Glx were positively correlated in both ROIs.
CONCLUSIONS: For the first time, GABA and Glx concentrations were compared between unmedicated depressed adults and controls in prefrontal ROIs. The abnormal reductions in Glx and GABA concentrations found in the MDD sample were compatible with findings from postmortem histopathologic studies, indicating that glial cell density is reduced in the same areas in MDD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17283286     DOI: 10.1001/archpsyc.64.2.193

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  276 in total

Review 1.  Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety.

Authors:  Xia Chen; Joop van Gerven; Adam Cohen; Gabriel Jacobs
Journal:  Acta Pharmacol Sin       Date:  2018-12-05       Impact factor: 6.150

2.  Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study.

Authors:  John C Umhau; Reza Momenan; Melanie L Schwandt; Erick Singley; Mariel Lifshitz; Linda Doty; Lauren J Adams; Valentina Vengeliene; Rainer Spanagel; Yan Zhang; Jun Shen; David T George; Daniel Hommer; Markus Heilig
Journal:  Arch Gen Psychiatry       Date:  2010-10

3.  Phase-adjusted echo time (PATE)-averaging 1 H MRS: application for improved glutamine quantification at 2.89 T.

Authors:  Andrew P Prescot; Todd Richards; Stephen R Dager; Changho Choi; Perry F Renshaw
Journal:  NMR Biomed       Date:  2012-03-12       Impact factor: 4.044

Review 4.  GABA-based evaluation of neurologic conditions: MR spectroscopy.

Authors:  L M Levy; A J Degnan
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-19       Impact factor: 3.825

Review 5.  In vivo magnetic resonance spectroscopy of GABA: a methodological review.

Authors:  Nicolaas A J Puts; Richard A E Edden
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2011-06-12       Impact factor: 9.795

Review 6.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 7.  Reconsidering anhedonia in depression: lessons from translational neuroscience.

Authors:  Michael T Treadway; David H Zald
Journal:  Neurosci Biobehav Rev       Date:  2010-07-11       Impact factor: 8.989

Review 8.  Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression.

Authors:  P Licznerski; R S Duman
Journal:  Neuroscience       Date:  2012-10-02       Impact factor: 3.590

9.  Glutamine deficiency in the prefrontal cortex increases depressive-like behaviours in male mice.

Authors:  Younghyurk Lee; Hyeonwi Son; Gyeongwha Kim; Sujeong Kim; Dong Hoon Lee; Gu Seob Roh; Sang Soo Kang; Gyeong Jae Cho; Wan Sung Choi; Hyun Joon Kim
Journal:  J Psychiatry Neurosci       Date:  2013-05       Impact factor: 6.186

10.  Biochemical abnormalities of the medial temporal lobe and medial prefrontal cortex in late-life depression.

Authors:  Talaignair N Venkatraman; Ranga R Krishnan; David C Steffens; Allen W Song; Warren D Taylor
Journal:  Psychiatry Res       Date:  2009-04-30       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.